InvestSMART

Fisher & Paykel Healthcare Corporation Limited (ASX:FPH)

ALERT: Price-sensitive ASX Announcement for FPH
Current share price for FPH : $32.930 5.4 (19.61%)+
Announcement
Release
26 May 2026 7:30AM
Price at Release
$27.530
Full Release
download
Summary
Fisher & Paykel Healthcare Corporation Limited reported strong financial performance for the year ended 31 March 2026, with total operating revenue reaching $2.31 billion, marking a 14% increase from the previous year. Net profit after tax rose by 24% to $468.5 million. The Hospital product group generated $1.51 billion in revenue, an 18% increase, while the Homecare product group saw an 8% increase to $802.7 million. The company invested $235.5 million, or 10% of revenue, in research and development. The final dividend per share increased by 38% to 33.0 cps, bringing the total dividend for the year to 52.0 cps. The gross margin improved to 63.7%, reflecting ongoing cost improvements and favorable currency impacts. Looking forward, the company expects to sustain its growth momentum in the next financial year, driven by innovation and global market presence. Fisher & Paykel Healthcare's products reached over 120 countries, supporting the care of 24 million patients, while the company continues to emphasize sustainable development and climate-related disclosures.
Key Points
  • Total operating revenue was $2.31 billion, a 14% increase from the previous year.
  • Net profit after tax increased by 24% to $468.5 million.
  • Revenue from the Hospital product group was $1.51 billion, an 18% increase.
  • Homecare product group revenue was $802.7 million, an 8% increase.
  • Investment in R&D was 10% of revenue, totaling $235.5 million.
  • Final dividend increased by 38% to 33.0 cps, total dividend for the year was 52.0 cps.
  • Gross margin improved to 63.7%.
  • The company anticipates continued growth for the next financial year.
  • Products were sold in over 120 countries, treating 24 million patients.
  • Commitment to sustainable development and climate-related disclosures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.